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ABSTRACT
Understanding the structure of PrPSc is without doubt a sine qua non to understand not only
PrPSc propagation, but also critical features of that process such as the strain phenomenon
and transmission barriers. While elucidation of the PrPSc structure has been full of difficulties,
we now have a large amount of structural information that allows us to begin to understand
it. This commentary article summarizes a round table that took place within the Prion 2018
meeting held in Santiago de Compostela to discuss the state of the art in this matter. Two
alternative models of PrPSc exist: the PIRIBS and the 4-rung β-solenoid models. Both of them
have relevant features. The 4-rung β-solenoid model agrees with experimental constraints of
brain derived PrPSc obtained from cryo-EM and X-ray fiber diffraction studies. Furthermore, it
allows facile accommodation of the bulky glycans that decorate brain-derived PrPSc. On the
other hand, the infectious PrP23-144 amyloid exhibits a PIRIBS architecture. Perhaps, both
types of structure co-exist.
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Introduction
‘It has not escaped our notice that the specific pairing we
have postulated immediately suggests a possible copying
mechanism for the genetic material’. With this famous
understatement, Watson and Crick reflected, in their clas-
sic 1953 paper, upon the fact that contemplation of the
structure of DNA, that they had just deciphered, was
sufficient to understand the mechanism by which this
molecule propagates [1]. PrPSc prions also propagate,
although what propagates in that case is not a primary
structure but rather the secondary, tertiary and quaternary
structures of a specific conformation of PrP [2]. For DNA,
pairing of the two helical chains within the double helix
underpins the templating mechanism. For PrPSc prions,
some specific elements within the PrPSc conformation
must underpin the capacity of this structure to mold an
incoming PrP molecule into a copy of itself. Thus, under-
standing the structure of PrPSc without doubt holds the key
to an immediate understanding of PrPSc propagation.
Furthermore, a number of critical features of the propaga-
tion process such as the strain phenomenon and
transmission barriers will be immediately understood
once the structure of PrPSc is known with sufficient detail.
Historically, the quest to elucidate the structure of
PrPSc has been a difficult one, given that PrPSc is an
analytical nightmare: difficult to isolate, insoluble in
water, polymeric, and featuring variable amounts of
post-translation modifications. Nevertheless, a large
amount of structural information and constraints
have been amassed over time by indefatigable
researchers, allowing us to begin to understand the
structure of this enigmatic molecule.
In this context, a round table took place within the
Prion 2018 meeting held in Santiago de Compostela
to discuss what we know about the structure of PrPSc.
Ilia Baskakov, Byron Caughey, Witold Surewicz, and
Holger Wille presented their points of view, under
the moderation of Alejandro M. Sevillano and Jesús
R. Requena. Ample participation by the audience in
the ensuing discussion ensured a wide representation
of different opinions. Here is a summary of the
discussion.
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1. Prion diversity
In addition to the generally intractable biophysical prop-
erties of PrPSc noted above, a number of other issues
complicate PrPSc structure determination. First is the
multitude of prion strains as well as disease-associated,
but not transmissible, aggregates of PrP that must be
explained. Many lines of evidence indicate that the PrPSc
of different prion strains has different underlying self-
propagating structures. Even for a given prion strain,
wide ranges of sizes, ultrastructures, and biochemical
characteristics have been observed, and some of these
characteristics can be profoundly affected by the type of
host animal, e.g. whether they expressed GPI-anchored
or anchorless PrPC [3]. Prion infectivity has been asso-
ciated with particles ranging from small non-fibrillar
PrP oligomers to amyloid fibrils hundreds of nm in
length [4]. This raises the question of whether this
range represents a size continuum of particles with
essentially the same core structure, or more fundamen-
tally distinct arrangements of monomers such as those
indicated by PrPSc preparations with both amyloid fibrils
and non-amyloid 2-D crystalline arrays (see below).
Synthetic recombinant PrP prions or prion-like fibrillar
assemblies have been described that can all propagate
indefinitely in vitro but, when inoculated into animals,
can range from being biologically inert to fully infec-
tious, pathogenic, and transmissible in subsequent pas-
sages [e.g. 5–13]. Recent evidence suggests that the
difference between these biological effects can some-
times be correlated with conformational differences
[14,15]. Collectively, the diversity of prions and prion-
like PrP assemblies suggest that there may be no single
PrPSc structure, and that diversity in conformation, and
even basic multimer architecture, should be anticipated.
Indeed, a number of fungal prions have been shown to
have parallel in-register intermolecular β-sheet (PIRIBS)
architectures [16], while another is a β-solenoid [17]. It is
notable that the latter, the [Het-s] prion of Podospora
anserina, is a functional, evolutionarily selected prion,
whereas most other prions, including the PrP-based
mammalian prions, are the accidental consequences of
the refolding of proteins that have quite distinct confor-
mations in their normal physiological states [16]. In any
case, much remains to be resolved about PrPSc structure
and the diversity thereof. Careful, unbiased and dispas-
sionate evaluation of emerging data, and empirically-
based models, should help us to solve the decades-long
mystery of the various ways in which PrP can misfold,
aggregate, and propagate to cause devastating neurode-
generative diseases.
2. The PIRIBS model
Although evidence suggests thatmany prionsmay have β-
solenoid architectures (see below), there is also clear evi-
dence that some PrP amyloids, both spontaneously
nucleated [18,19] and prion-seeded [10] recombinant
PrP amyloids can have PIRIBS architectures. These con-
clusions were discerned primarily from site-specific spin-
labeling [18] and solid-state NMR experiments [10,19],
which allowed determination of the basic architecture of
the multimers without providing all-encompassing ato-
mistic structures. In silico models of such structures are
consistent with many empirical descriptors and con-
straints on PrPSc structures and appear to provide
a plausible molecular basis for faithfully templated strain
propagation [10]. However, as detailed in the following
sections, PIRIBSmodels are not obviously consistent with
evidence for 2D crystals, a 19.2 Å repeating unit along the
fibril axis, or maximal glycosylation of all PrP monomers,
as appears to be the case with some prion strains. Thus,
although PIRIBS fibrils of PrP can easily be made and
propagated in vitro, it remains to be determined whether
such structures represent any of the diverse pathological
self-propagating PrP aggregates of natural prion diseases.
3. The 4-rung β-solenoid model
The hypothesis that the structure of PrPSc is based on a β-
helix or β-solenoid fold arose from studies of an alternative
polymerization state for the N-terminally truncated PrP
27–30 [20]. Traditionally, PrP 27–30 polymerized into
amyloid fibrils termed ‘prion rods’ [21], but here two-
dimensional (2D) crystals formed by PrP 27–30 trimers
were observed. By comparing the PrP 27–30 2D crystals
with isomorphic 2D crystals from a redacted ‘mini-prion’
(PrPSc106) [22,23], it became apparent that traditional (i.e.
elongated) β-strand architectures could not accommodate
the tight packing of protein molecules within the 2D crys-
tals. Difference mapping between 2D crystals from these
two prion forms allowed the creation of the first molecular
model that included a β-helix architecture [20]. A further
refinement of the electron microscopy-based analyzes and
the modeling approach restricted the β-helix portion to
a compact, four-rung β-helix fold [24]. In subsequent
years, a variety of alternate models based on the β-helix
or β-solenoid hypothesis were published (reviewed in 25).
The original β-helix models still retained some α-helices
(the C-terminal helices B and C) from the native PrPC
structure [20,24], but a thorough re-evaluation of pre-
viously published spectroscopy data [25,26] and new H/
D-exchange experiments argued against this assumption
[27]. Nevertheless, the data re-evaluation and the new
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experiments were still compatible with the β-helix/β-
solenoid hypothesis, but reduced the number of restraints
as the previously α-helical part of the protein became now
available to adopt β-sheet structure as well.
Additional support for the β-helix hypothesis origi-
nated from X-ray fiber diffraction experiments, which
revealed that the PrPSc- and PrP 27–30-fold contains
a four-rung β-solenoid architecture at its core [28]. The
diffraction patterns included a series of reflections at
9.6, 6.4, and 4.8 Å, which corresponded to the second,
third, and fourth order signals of a 19.2 Å repeating
unit (i.e. 4 times 4.8 Å). Even the ‘mini-prion’ was
found to include a four-rung β-solenoid core [29],
which by itself is incompatible with any presumed,
residual α-helices as the ‘mini-prion’ can only adopt
a four-rung β-solenoid fold if those residues are
included in the β-structure.
Next, limited proteolysis followed by mass spectro-
metry was used to locate loops and (partially) exposed
residues in PrP 27–30 that could be cleaved by protei-
nase K [30]. The judicious use of denaturing conditions
rendered the usually compact PrP 27–30-fold more
amenable to this type of analysis. The resulting proteo-
lytic fragments were compatible with the four-rung β-
solenoid architecture, and a rough threading of the PrP
primary structure onto this fold was developed [31].
Most recently cryo electron microscopy was employed
to analyze the structure of PrP 27–30, and the results were
found to be fully compatible with a four-rung β-solenoid
architecture at the core of the infectious prion [32]. Here,
a GPI-anchorless variant of PrP was used [3], which
reduced the complexity of the resulting amyloid fibrils.
Electron micrographs of individual amyloid fibrils were
used to generate three-dimensional (3D) reconstructions,
revealing the presence of two protofilaments. The protein
density in these protofilaments could only be accommo-
dated with the physical dimensions and an observed aver-
age molecular height of 17–19 Å, if a four-rung β-solenoid
architecture was assumed [32]. Lastly, the β-solenoid
hypothesis provides constraints for the replication of
prions that involves templating on the first and/or last
rung of the β-solenoid structure [33]. The steric constraints
on the templating process that result as a consequence of
the molecular architecture will be informative for future,
higher-resolution analyzes of the structure of PrPSc.
4. Constraints imposed by glycosylation
Several structural models of PrPSc that exhibit diverse
PrP folding patterns including parallel in-register β-
structures and two-, three- or four-rung β-solenoids
have been proposed in recent years (reviewed in 33).
In an effort to build a realistic molecular model of
PrPSc, our knowledge about PrPSc glycosylation should
be taken into consideration. The first question to ask, is
which of the proposed models can accommodate
N-linked glycans? To address this question, a tri-
antennary glycan with a size average of those found in
PrP sialoglycoforms was used for modeling PrPSc [34].
In-register parallel β-sheet structure, the glycans of
neighboring PrP molecules have to be spaced at
a distance of 4.7 Å bringing them into substantial
spatial overlap that precludes such arrangements [34].
Considerable spatial overlap between glycans still exists
in two-rung solenoid that separates glycans at
a distance of 2 × 4.7 Å. However, three- or four-rung
solenoids permit recruitment of diglycosylated PrP
molecules [34]. The result of modeling supports the
hypothesis that glycans limit the diversity of folding
patterns accessible to glycosylated PrPC.
To better understand how glycans might be enrolled in
defining strain-specific PrPSc structures, two alternative
views can be considered. According to one view, prion
strains can partially overcome constraints imposed by
glycans by selectively recruiting mono- and un-
glycosylated PrPC sialoglycoforms at the expense of digly-
cosylated sialoglycoforms. Only those PrPC glycoforms
are recruited that fit into strain-specific PrPSc structures.
Alternative view proposes that recruitment is not selec-
tive, i.e. PrPC sialoglycoforms are incorporated into PrPSc
proportionally to their relative presentations in a pool of
PrPC molecules expressed in a cell. If this is the case, the
spectrum of PrPSc structures is limited to those that can
accommodate all sialoglycoforms. To answer the question
on selectivity of recruitment, composition of PrPSc sialo-
glycoform was analyzed using 2D gels [35,36]. Because
N-linked glycans carry negatively charged sialic acid resi-
dues, the sialoglycoforms can be separated in horizontal
dimension of 2D according to their charge [37]. The 2D
analysis revealed that PrPSc strains exhibits broad range of
strain-specific selectivity with respect to PrPC sialoglyco-
forms [34,35]. Consistent with the first mechanism,
a group of strains shows strong preferences, as they
excluded highly sialylated molecules as well as diglycosy-
lated molecules [34,35]. At the same time, in support of
the second mechanism, a group of strains did not display
any preferences with respect to glycosylation or sialylation
status [34,35]. Analysis across all examined strains
revealed a great correlation between glycosylation and
sialylation status of PrP sialoglycoforms within PrPSc
[34,35]. This analysis also demonstrated a broad range
of selectivity displayed by prion strains in recruiting PrPC
sialoglycoforms, ranging from non-selective to highly
selective. Notably, for the group of non-selective strains,
the composition of sialoglycoforms within PrPSc was very
similar to that of PrPC.
48 I. V. BASKAKOV ET AL.
A broad range of selectivities displayed by prion
strains could be attributed to strain-specific variations
in quaternary structures and does not require signifi-
cant variations in strain-specific folding patterns
(Figure 1). In particular, quaternary assembly of non-
selective strains could involve considerable twist or
rotation between neighboring PrP molecules. Owing
to such rotations, glycans of neighboring PrP molecules
extend into different directions avoiding spatial inter-
ference and minimizing electrostatic repulsion between
sialic acid residues (Figure 1). In strains that select
against diglycosylated and highly sialylated PrPC, the
rotation between neighboring PrP molecules is pro-
posed to be very small or absent. Such modes of assem-
bly can create spatial and electrostatic interference
between glycans and limit recruitment of diglycosylated
and highly sialylated PrPC (Figure 1). The three- or
four-rung solenoid models offer the best opportunity
for accommodating both selective and non-selective
strains.
To summarize our view on constraints imposed by
glycosylation, prion strains display a broad range of
selectivity toward PrPC sialoglycoforms. Some strains
recruit sialoglycoforms proportionally to their presen-
tation in PrPC, whereas others avoid diglycosylated and
highly sialylated PrPC isoforms. Strain-specific ratio of
the glycoforms within PrPSc is a result of negative
selection of heavily sialylated PrP molecules with
bulky glycans. The extent to which heavily sialylated
glycoforms are excluded is believed to be controlled by
a strain-specific structure. Glycan volume and electro-
static repulsion due to sialylation have to be taken into
consideration for modeling PrPSc structures.
5. Lessons from studies with PrP23–144 amyloid
fibrils
An important aspect of human prion diseases is the
presence of a large number of mutations in the
human PrP gene (PRNP) that segregate with familial
CJD, Gerstmann-Sträussler-Scheinker (GSS) disease
or fatal familial insomnia. All these disorders are
autosomal dominant. One of these disease-related
mutations, associated with GSS-like subtypes, is the
tyrosine to stop codon mutation at position 145,
resulting in a C-terminally truncated PrP fragment
corresponding to residues 23–144 (PrP23-144) (38;
39). Bacterially expressed recombinant PrP23-144
from different species readily form amyloid fibrils
under physiologically relevant conditions, and studies
in vitro with this truncated PrP variant provided
important insights into mechanistic principles of the
conformational basis of species- and strain-
dependent seeding specificity of prion protein amy-
loids [40,41].
The potential value of PrP23-144 amyloid as a model
for exploring molecular aspects of mammalian prion
propagation is further indicated by recent studies show-
ing that mouse PrP23-144 fibrils are infectious, causing
clinical prion disease in mice [42]. An intriguing and
highly unusual feature of the latter disease is the accu-
mulation in mouse brain of two types of self-
propagating PK-resistant PrP fragments: one of them
about 6–7 kDa in size (with N- and C-termini mapping
to residues ~80–89 and 150–159, respectively) and
the second one with molecular mass upon deglycosyla-
tion of ~17–18 kDa. While the shorter fragments are
reminiscent of human PrPres in GSS subtypes, the
longer fragments are similar to those observed in clas-
sical mouse-adapted scrapie strains.
The finding that PrP23-144 fibrils are infectious is of
particular importance given that, in contrast to fibrils
formed from full-length PrP, the former fibrils give rise
to high quality solid-state NMR (ssNMR) spectra and,
thus, are amenable to high-resolution structural char-
acterization. Different types of ssNMR studies with
human PrP23-144 amyloid fibrils published over the
past ten years revealed that (i) The rigid β-core of the






Figure 1. Schematic diagram illustrating differences in quatern-
ary assembly between non-selective (left panels) and selective
(right panels) strains. Non-selective strains can accommodate
diglycosylated sialoglycoforms due to rotation between neigh-
boring PrP molecules that allows spatial separation of glycans.
In selective strains, the rotation between neighboring PrP mole-
cules is very small (a) or absent (b). Recruitment of diglycosy-
lated molecules by selective strains would lead to spatial
interference between glycans (c). Negative selection of diglyco-
sylated molecules helps to minimize spatial and electrostatic
interference between glycans (d).
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segment that maps to residues ~112–140, with the
reminder of the protein dynamically disordered; (ii)
This rigid core region consists of three β-strands
encompassing residues ~112–113 (strand 1), ~120–123
(strand 2), and ~130–140 (strand 3); and (iii) The core
region displays a parallel in-register organization of β-
strands [43–45]. Furthermore, a recently published
structural model [46] reveals that these fibrils consist
of two protofilaments with β-sheet regions running
parallel to the long fibril axis. The compact hydropho-
bic core of constituent monomers consists of Ala, Gly
and Val-rich segment between residues ~115–122, and
this structure is stabilized by a highly specific interac-
tion between the side chains of Ala117 in this hydro-
phobic core and Ile139 in the longest β-strand.
Interestingly, a GSS-related substitution of Ala117
with Val disrupts this stabilizing interaction, resulting
in a different amyloid fold. Apart from this high-
resolution insight into the structure of human PrP23-
144 amyloid, ssNMR studies also revealed the nature of
structural differences between PrP23-144 amyloid
fibrils from different species, providing a structural
basis for understanding species-dependent seeding bar-
riers [45].
Even though mouse PrP23-144 amyloid fibrils can
seed in vivo the conversion of full-length PrP to an
infectious, self-propagating structure that displays PK-
resistance similar to that of classical scrapie strains, it is
at present unknown whether the product of this seed-
ing reaction retains the parallel in-register structural
motif of the seed. In any case, structural and biological
data for PrP23-144 amyloid clearly indicate that prion
protein fibrils with parallel in-register organization can
be infectious. Combined with recent evidence for a β-
solenoid structure of anchorless prions, this raises an
intriguing possibility that entirely different structural
motifs may be present in distinct prion strains.
Conclusions
The earlier large trove of structural models of PrPSc [47]
has now shrunk to only two remaining models: the PIRIBS
and the 4-rung β-solenoid models. Both of them have
important features that make them relevant. The 4-rung β-
solenoid model agrees with experimental constraints of
brain derived PrPSc obtained through cryo-EM and
X-ray fiber diffraction studies [28,32]. Furthermore, it
allows facile accommodation of the bulky glycans present
in brain-derived PrPSc [34]. However, the PrP23-144 amy-
loid, which exhibits a PIRIBS architecture [46] has also
been demonstrated to be infectious [42]. How can these
facts be reconciled? The most parsimonious explanation is
that both types of structure co-exist. The first recombinant
PrP prions were generated in 2004 using a technique that
is known to yield amyloid fibers [5]. In retrospect, it is
likely that these prions were structurally similar to amy-
loids produced at the later time, whose architecture is
known to conform to the PIRIBS model, as assessed by
site-directed spin labeling, solid-state NMR [10,18,19], and
X-ray fiber diffraction analyzes [28]. In some cases, such
PrP amyloids can propagate in the brain of recipient
experimental animals without causing a clinical disease
(v.g. 11,13). Atypical PrPres is one of the example of self-
replicating and transmissible, yet clinically silent state [48–
50]. However, upon second or third passage they evolve to
classical PrPSc prions that lead to TSE disease [13,17,49–
51]. This conformational transformation can be easily
tracked biochemically, as the pattern of PK-resistant frag-
ments evolves throughout passages. Therefore, it is con-
ceivable that different types of PrP amyloids with
a propagative, infectious properties can co-exist in the
brain. Even though some of them exhibit a PIRIBS archi-
tecture, it is likely that the most infectious ones might
exhibit an alternative 4-rung β-solenoid structure.
Furthermore, PIRIBS structures might be able to template
4-rung β-solenoids and 4-rung β-solenoids might template
PIRIBS amyloids, as was seen in the amyloid seeding assay
[52]. The deformed templating model might provide
a useful framework for explaining mutual templating of
self-propagating structures with alternative folding pat-
terns [53]. To add further layers of complexity, different
subtypes of PIRIBS and 4-rung β-solenoid conformations/
architectures might have different degrees of infectivity,
and some of them may be even innocuous while main-
taining the capacity to self-propagate [11,13,14,49].
However, it should be remembered that infectivity is an
operational, not an absolute property of a potentially infec-
tious agent. In this respect, thousands of British citizens
are believed to harbor PrPSc in their bodies, but it will
hopefully not cause any clinical neurodegenerative disease
in their lifetime [54]. In this context, it might be necessary
to acknowledge that PrPSc is not the only infectious PrP
amyloid, that in fact some PrPSc strains and/or subtypes
can propagate within brains without causing disease, just
as some other propagative PrP amyloids that are not PrPSc,
and that interconversions among these could happen. In
other words, that the terms ‘PrPSc’ and ‘PrP prion’ might
perhaps not be synonyms.
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